BioNotebook: Valeant back to black in 4Q; Forest submits NDA; Sunesis, Inovio, Oncolytics raise cash; Anacor Phase III plan
This article was originally published in Scrip
Valeant turns a profit at year's end; Forest submits nebivolol/valsartan NDA; Sunesis, Inovio price offerings; Lincoln Park commits $26m to Oncolytics; and FDA signs off Anacor's Phase III plan.
You may also be interested in...
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.